Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 582-589

  Onyenadum, A ^a   Gogas, H ^a   Markopoulos, C ^a   Bafaloukos, D ^a   Aravantinos, G ^a   Mantzourani, M ^a   Koutras, A ^a   Tzorakoelefterakis, E ^a   Xiros, N ^a   Makatsoris, T ^a   Fountzilas, G ^a   Kalofonos, H P ^a,b  

^a Hellenic Cooperative Oncology Group   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Metastatic breast cancer; Mitoxantrone; Vinorelbine

Indexed keywords

MITOXANTRONE; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ELECTROCORTICOGRAPHY; FATIGUE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 36549075562     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.582     Document Type: Article

References (30)

1. Greenlee RT, Murray T, Bolden S. Cancer statistics. Cancer J Clin 2000;50:7-33.
2. Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22 (suppl 5 ): 5-21.
3. Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994; 21:19-24.
4. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-9.
5. Silvestris N, D'Aprile M, Andreola G, et al. Rationale for the use of gemcitabine in breast cancer (Review). Int J Oncol 2004; 24:389-98.
6. Smith IE, Stuart-Harris R, Pavlidis N, et al. Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 1983; 10:37-40.
7. Robertson JF, Williams MR, Todd JH, et al. Mitoxantrone is a useful palliative therapy in advanced breast cancer. Am J Clin Oncol 1989; 12:393-6.
8. Brufman G, Haim N, Ben-Baruch N, et al. Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. J Chemother 1993;5:43-6.
9. Susnjar S, Vasovic S, Neskovic-Kostantinovic Z, et al. Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: a phase II study. Tumori 1999;85:478-82.
10. Vogel Cl. Combination of chemotherapy with vinorelbine and mitoxantrone for metastatic breast cancer: a review. Sem Oncol 1995;22 (Suppl.) 5: 61-65.
11. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995;18(5):392-6.
12. Fumoleau P, Delgado T, Delozier A, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11: 1245-52.
13. Romero A, Rabinovich M, Vallejo C, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-41.
14. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995;13(11):2722-30.
15. Llombart-Cussac A, Pirot X, Rhor-Alvarado A et al: First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study. Oncology 1998;55: 384-90.
16. Peacock NW, Burris HA, Dieras V, et al. A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Invest New Drugs. 1998; 16(1): 37-43.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457-481.
18. Lentner C. Geigy Scientific Tables ('Exact Confidence Limits for p'); Ciba-Geigy: Switzerland, 1982: 89 - 102.
19. Namer M, Soler-Michel P, Turpin F, et al. Results of phase III prospective, randomized trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in first-line therapy of metastatic breast cancer. Eur J Cancer 2001; 37 (9): 1132 - 1140.
20. Berruti A, Sperone P, Bottini A et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000; 18: 3370 - 3377.
21. Adams DJ, Knick VC. P - glycoprotein mediated resistance to 5-nor-aughydro-vinblastine (Navelbine). Invest New Drugs 1995; 13: 13-21.
22. Zelek L, Barthier S, Riofrio M et al: Weekly Vinorelbine is an effective palliative regimen offer failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92: 2267 - 2272.
23. Gasparini G, Caffo O, Barni S et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 1994; 12:2094 - 2101.
24. Terenziani M, Demicheli R, Brambilla C et al. Vinorelbine: An active non-cross resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat 1996; 39: 285 - 291.
25. Terzoli E, Nistico C, Fabi A, et al. Single agent vinorelbine in pretreated breast cancer patients comparison of two different schedules. J Exp Clin Cancer Res 2004; 23 (2): 207-213.
26. Toi M, Saeki T, Aogi K, et al. Late phase II clinical study of Vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracycline and taxanes. Jpn J Clin Oncol 2005; 35 (6): 210-315.
27. Dinota A, Bilancia D, Romano R, et al. Biweekly administration of gemcitabine and vinorelbine as first-line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 2005; 89 (1): 1-3.
28. Konig E, Kurbacher C, Schwonzen M, et al. A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. Anticancer Drugs 2002; 13 (8): 827-832.
29. Di Constanzo F, Manzione L, Gasperoni S, et al. Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research. Cancer Invest 2004; 22 (3); 331-337.
30. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous Vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinevian Breast Group Trial (SOG9403). J Clin Oncol 2004; 22 (12): 2313-2320.